Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-40
Closed -$29 10211
2025
Q1
$29 Hold
40
﹤0.01% 10056
2024
Q4
$48 Buy
+40
New +$112 ﹤0.01% 9707
2024
Q3
Sell
-936
Closed -$5.1K 9454
2024
Q2
$5.1K Buy
936
+908
+3,243% +$5.1K ﹤0.01% 8023
2024
Q1
$148 Buy
+28
New +$159 ﹤0.01% 8778
2023
Q2
Sell
-4,707
Closed -$35.1K 8834
2023
Q1
$35.1K Buy
4,707
+1,398
+42% +$14K ﹤0.01% 6687
2022
Q4
$41K Buy
+3,309
New +$58.1K ﹤0.01% 6953
2022
Q2
Sell
-4,486
Closed -$196K 10248
2022
Q1
$196K Sell
4,486
-5
-0.1% -$217 ﹤0.01% 5386
2021
Q4
$248K Buy
+4,491
New +$277K ﹤0.01% 5500
2021
Q2
Sell
-1,393
Closed -$110K 9343
2021
Q1
$110K Buy
1,393
+750
+117% +$48.7K ﹤0.01% 5891
2020
Q4
$37K Buy
643
+603
+1,508% +$28.4K ﹤0.01% 6443
2020
Q3
$1K Sell
40
-1,709
-98% -$64.7K ﹤0.01% 7757
2020
Q2
$81K Sell
1,749
-1,558
-47% -$43.4K ﹤0.01% 5467
2020
Q1
$53K Sell
3,307
-5,284
-62% -$126K ﹤0.01% 5786
2019
Q4
$235K Buy
8,591
+2,849
+50% +$76.2K ﹤0.01% 5490
2019
Q3
$169K Buy
5,742
+4,616
+410% +$137K ﹤0.01% 5374
2019
Q2
$32K Buy
1,126
+986
+704% +$33.2K ﹤0.01% 6279
2019
Q1
$6K Buy
140
+100
+250% +$3.6K ﹤0.01% 7065
2018
Q4
$1K Sell
40
-751
-95% -$27.9K ﹤0.01% 7873
2018
Q3
$34K Sell
791
-4,366
-85% -$124K ﹤0.01% 6443
2018
Q2
$85K Buy
5,157
+5,077
+6,346% +$107K ﹤0.01% 5566
2018
Q1
$2K Buy
80
+40
+100% +$755 ﹤0.01% 7515
2017
Q4
$1K Sell
40
-166
-81% -$3.15K ﹤0.01% 7689
2017
Q3
$5K Sell
206
-80
-28% -$1.73K ﹤0.01% 7202
2017
Q2
$6K Buy
+286
New +$6.35K ﹤0.01% 7028
2017
Q1
Sell
-275
Closed -$5K 7595
2016
Q4
$5K Sell
275
-32
-10% -$690 ﹤0.01% 7229
2016
Q3
$9K Buy
307
+25
+9% +$701 ﹤0.01% 6830
2016
Q2
$7K Buy
282
+82
+41% +$3K ﹤0.01% 6955
2016
Q1
$7K Sell
200
-213
-52% -$8.03K ﹤0.01% 6833
2015
Q4
$29K Buy
413
+178
+76% +$12.1K ﹤0.01% 6355
2015
Q3
$14K Buy
235
+141
+150% +$17.5K ﹤0.01% 7003
2015
Q2
$13K Buy
94
+37
+65% +$3.55K ﹤0.01% 7242
2015
Q1
$4K Buy
+57
New +$3.52K ﹤0.01% 8194

Other funds holding AFMD

UBS Group's AFMD Position: Q2 2025 in Review

UBS Group sold out of Affimed (AFMD) in Q2 2025, closing a stake of 40 shares — an estimated $29 sold.

UBS Group first reported a position in AFMD in Q1 2015 and held it in 32 quarters. The position peaked at $248K in Q4 2021. 3 funds tracked by Wall St. Rank hold AFMD as of Q2 2025.

  • UBS Group reported no remaining Affimed position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 40 Affimed shares in Q2 2025, an estimated $29.
  • UBS Group first reported a position in Affimed in Q1 2015 and held it in 32 quarters.
  • UBS Group's Affimed position peaked at $248K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Affimed as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.